maladies – Accès aux traitements innovants relatifs aux mutations du cancer du poumon

This written question asks about improving access to innovative treatments for lung cancer patients with specific genetic mutations. It highlights the need for timely and equitable access to these advanced therapies. The question seeks to understand the government's strategy for ensuring patients can benefit from new treatments, potentially impacting healthcare providers and pharmaceutical companies.